ArticleTranslational lung cancer research2026
Perioperative anxiety and depression predict long-term survival after neoadjuvant therapy in non-small cell lung cancer: a multicenter analysis.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emotional distress and clinical response to neoadjuvant chemoimmunotherapy in resectable non-small-cell lung cancer: a protocol for the prospective observational NeoFUSE-Lung cohort study.Translational lung cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anxiety and depression are common yet not timely valued in thoracic oncology. The prognostic value of perioperative trajectories of anxiety and depression has not been well-quantified in neoadjuvant-treated. This study aimed to evaluate whether perioperative anxiety and depression independently predict overall survival (OS) in non-small cell lung cancer (NSCLC) patients receiving neoadjuvant therapy and surgery, and to build a pragmatic prognostic nomogram. Methods: We retrospectively analyzed 167 consecutive NSCLC patients from three tertiary centers (Jan 2018 to Feb 2024). Psychological status was assessed at baseline, preoperatively, and 3-month postoperatively using the Hospital Anxiety and Depression Scale (HADS). Receiver operating characteristic (ROC) analyses defined high-risk cut-offs. OS was estimated by Kaplan-Meier and compared by log-rank; predictors were assessed with Cox models. A nomogram integrating psychological and pathological variables underwent internal validation (bootstrap, calibration, time-dependent ROC, decision-curve analysis). Results: Optimal HADS-Anxiety (HADS-A) thresholds were 5.5 (baseline), 4.5 (preoperative), and 7.5 (3-month postoperative); HADS-Depression (HADS-D) thresholds were 3.5, 5.5, and 7.5 (all P<0.001). During follow-up, 45 patients recurred and 27 died (all cancer-related); mean follow-up was 38.65 months, and estimated 1-, 3-, and 5-year OS was 95.81%, 86.23%, and 83.83%. In multivariable analysis, post-neoadjuvant pathologic tumor lymph nodes metastasis (ypTNM) stage III [hazard ratio (HR) =5.72; 95% confidence interval (CI): 2.05-15.97; P<0.001], baseline HADS-A >5.5 (HR =4.59; 95% CI: 1.01-20.77; P=0.048), and 3-month HADS-A >7.5 (HR =7.50; 95% CI: 2.85-19.71; P<0.001) independently predicted worse OS, whereas HADS-D did not. The nomogram achieved areas under the curves (AUCs) of 0.89, 0.90, and 0.89 for 1-, 2-, and 3-year OS and outperformed ypTNM alone [concordance index (C-index) 0.85 Conclusions: Perioperative anxiety, particularly at baseline and 3-month postoperatively, provides independent prognostic information beyond staging in neoadjuvant-treated NSCLC. Incorporating perioperative anxiety assessment into oncologic pathways may improve prognostic precision and inform personalized perioperative interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.